Did You Know?

Editor’s Picks

Latest News

SCYNEXIS Secures Additional Commercial Insurance Formulary Coverage for BREXAFEMME® (ibrexafungerp tablets), Providing Access to an Estimated 93 Million Commercially-Insured Lives

Advanced first-in-class, one-day oral antifungal treatment, BREXAFEMME is now covered for approximately 55 percent of commercially-insured U.S. patientsJERSEY CITY, N.J.,...

Syneos Health Promotes Baba Shetty to President, Technology and Data Solutions, and Suma Ramadas to Executive Vice President, Medical Affairs

MORRISVILLE, N.C., April 19, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced...

error: Content is protected !!